OOIR: Observatory of International Research

Papers

(The H4-Index of BMC Medical Research Methodology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Estimation of marginal structural models under irregular visits and unmeasured confounder: calibrated inverse probability weights	471
A Bayesian network perspective on neonatal pneumonia in pregnant women with diabetes mellitus	236
Statistical methods in the analysis of multicentre HIV randomized controlled trials in the African region: a scoping review	188
CalScope: methodology and lessons learned for conducting a remote statewide SARS-CoV-2 seroprevalence study in California using an at-home dried blood spot collection kit and online survey	184
Technologies for frailty, comorbidity, and multimorbidity in older adults: a systematic review of research designs	126
Clinical systematic reviews – a brief overview	113
How likely is unmeasured confounding to explain meta-analysis-derived associations between alcohol, other substances, and mood-related conditions with HIV risk behaviors?	111
regCOVID: Tracking publications of registered COVID-19 studies	110
Correction: In health research publications, the number of authors is strongly associated with collective self-citations but less so with citations by others	105
Could master protocols be adapted for effectiveness-implementation hybrid studies?	105
Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study	91
Estimating comparative effectiveness using Single-Arm trials: A challenge in the field of agnosticism	89
Improving the efficiency of drug resistant tuberculosis treatment trials: a time-to-event alternative marker for bacteriological response and adaptive minimization for randomization	85
Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group	85
The impact of iterative removal of low-information cluster-period cells from a stepped wedge design	74
Modelling of intensive care unit (ICU) length of stay as a quality measure: a problematic exercise	73
MetaAnalyst: a user-friendly tool for metagenomic biomarker detection and phenotype classification	71
A gated group sequential design for seamless Phase II/III trial with subpopulation selection	69
Developing survey weights to ensure representativeness in a national, matched cohort study: results from the children and young people with Long Covid (CLoCk) study	65
Design and analysis of outcomes following SARS-CoV-2 infection in veterans	63
Causal effect of chemotherapy received dose intensity on survival outcome: a retrospective study in osteosarcoma	61
Understanding facilitators of research participation among adults with self-reported chronic pain – a survey examining hypothetical research participation	58
A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point	55
Comparing methods for handling missing data in electronic health records for dynamic risk prediction of central-line associated bloodstream infection	55
Recruitment of a probability-based general population health panel for public health research in Germany: the panel ‘Health in Germany’	52

Choices of measures of association affect the visualisation and composition of the multimorbidity networks	51
Towards robust electronic health record systems: integrating formal verification and process modeling techniques	50
Contextual effects: how to, and how not to, quantify them	50
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased	50
External validation of existing dementia prediction models on observational health data	47
The role and challenges of clinical research coordinators: insights from a national survey	46
Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk	46
A study within a trial (SWAT) of clinical trial feasibility and barriers to recruitment in the United Kingdom – the CapaCiTY programme experience	44
Fidelity, pragmatism and the “grey line” in between—exploring the delivery of a pragmatic physical activity randomised controlled trial—a secondary analysis	44
An algorithm to assess importance of predictors in systematic reviews of prediction models: a case study with simulations	41
Causal estimation of time-varying treatments in observational studies: a scoping review of methods, applications, and missing data practices	40
Using joint models to study the association between CD4 count and the risk of death in TB/HIV data	40
Random-effects meta-analysis models for pooling rare events data: a comparison between frequentist and bayesian methods	40
Response to “The importance of considering variability in re-expression of effect estimates for use in meta-analysis.” (Kopylev and Dzierlenga 2025)	39
Mediation analysis to identify causes of racial disparity in health outcomes: a comparison of model-based and outcome-based approaches	39
The choice of time scales in survival analysis has implications: calendar time versus patients’ time-to-event	39
Measuring the impact of zero-cases studies in evidence synthesis practice using the harms index and benefits index (Hi-Bi)	39